CG Oncology, Inc. (CGON) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, CG Oncology reported revenue of $4.0M, up 254.7% from $1.1M the year before. Net income was -$161.0M (a -3985.0% net margin), or -$2.08 per diluted share. Operating margin was -4722.1%. Operating activities generated -$132.3M of cash, leaving -$132.4M of free cash flow. At fiscal year end, CG Oncology held $791.6M in total assets against $39.0M in total liabilities, including $32.5M of cash and equivalents.
Open the full interactive CG Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
CG Oncology Key Stats
| Share Price | $62.40 |
|---|---|
| Market Cap | $5.50B |
| Revenue YoY Growth | +254.7% |
| 52-Week Range | $37.37 – $80.68 |
| Shares Outstanding | 88.2 million (basic, 2026 Q2) |
CG Oncology Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $1.1M | $4.0M |
| Operating Income | -$114.7M | -$190.8M |
| Pre-Tax Income | -$88.0M | -$161.3M |
| Income Tax | — | -$270,000 |
| Net Income | -$88.0M | -$161.0M |
| Diluted EPS | -$1.41 | -$2.08 |
CG Oncology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.7M | $2.3M | $1.1M | $1.2M |
| Net Income | -$43.8M | -$41.3M | -$60.2M | -$79.1M |
| Diluted EPS | -$0.57 | -$0.53 | -$0.71 | -$0.90 |
CG Oncology Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $257.1M | $32.5M |
| Current Assets | $754.2M | $759.5M |
| Total Assets | $754.8M | $791.6M |
| Current Liabilities | $21.4M | $30.8M |
| Total Long-Term Debt | — | $3.0M |
| Total Liabilities | $21.4M | $39.0M |
| Shareholders' Equity | $733.4M | $752.6M |
CG Oncology Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$78.7M | -$132.3M |
| Cash From Investing | -$300.8M | -$245.8M |
| Cash From Financing | $628.3M | $153.6M |
| Free Cash Flow | -$78.9M | -$132.4M |
Figures from CG Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full CG Oncology financials page for every line item.
CG Oncology Company Profile
| Ticker | CGON |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Dallas, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001991792 |
Frequently Asked Questions
What was CG Oncology's revenue in fiscal 2025?
CG Oncology (CGON) reported revenue of $4.0M for fiscal 2025.
What was CG Oncology's net income in fiscal 2025?
CG Oncology reported net income of -$161.0M for fiscal 2025.
What was CG Oncology's earnings per share (EPS) in fiscal 2025?
CG Oncology's diluted EPS was -$2.08 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did CG Oncology generate in fiscal 2025?
CG Oncology generated -$132.4M of free cash flow in fiscal 2025.
What was CG Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q2), CG Oncology reported revenue of $1.2M.
How much debt does CG Oncology have?
CG Oncology reported $3.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of CG Oncology are outstanding?
CG Oncology reported a weighted average of 88.2 million basic shares outstanding in 2026 Q2.
What is CG Oncology's market cap?
Based on its latest closing price, CG Oncology (CGON) has a market capitalization of about $5.50B.
When does CG Oncology's fiscal year end?
CG Oncology's fiscal year end, as registered with the SEC, is December 31.
Where is CG Oncology headquartered?
CG Oncology lists its business address in Dallas, Texas in its SEC filings.
CG Oncology Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →